Treatment of post-bariatric hypoglycemia with exendin (9-39)

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 12102663
APP PUB NO 20240000894A1
SERIAL NO

18172546

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compositions and methods for treating hyperinsulinemic hypoglycemia, such as hyperinsulinemic hypoglycemia after bariatric surgery, are provided. In some embodiments, an effective amount of the glucagon-like peptide-1 receptor antagonist exendin(9-39) is subcutaneously administered twice per day.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYOFFICE OF THE GENERAL COUNSEL BUILDING 170 3RD FLOOR MAIN QUAD P O BOX 20386 STANFORD CA 94305

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Craig, Colleen M Stanford, US 13 55
McLaughlin, Tracey L Stanford, US 12 55

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Apr 1, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 1, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 1, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00